Synthekine

Blood cancer
#Blood cancer #CAR-T #Cell therapy #Haematology #Oncology #Phase I trial #Synthekine

Positive initial results from trial of CD19 CAR-T in blood cancers

Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies.  In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More

#Cancer Research #News

#Autoimmune disease #CAR-T #Cell therapy #FDA #Lupus #Synthekine

CAR-T and orthogonal IL-2 therapy for lupus fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted fast track designation to SYNCAR-001 + STK-009. The treatment is indicated for patients with severe, refractory systemic lupus erythematosus (SLE), without the use of lymphodepletion. The fast-track designation follows investigational new drug (IND) clearance for a Phase I study evaluating SYNCAR-001… Read More

#News #Regulatory